A BILL 
To authorize a study on certain exemptions for treatment 
of opioid use disorder through opioid treatment programs 
during the COVID–19 public health emergency, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Opioid Treatment Ac-
4
cess Act of 2022’’. 
5
22:28 Jul 22, 2022
H6279
2 
HR 6279 IH1S 
SEC. 2. STUDY ON EXEMPTIONS FOR TREATMENT OF 
1
OPIOID USE DISORDER THROUGH OPIOID 
2
TREATMENT PROGRAMS DURING THE COVID– 
3
19 PUBLIC HEALTH EMERGENCY. 
4
(a) STUDY.—The Assistant Secretary for Mental 
5
Health and Substance Use shall conduct a study, in con-
6
sultation with patients and other stakeholders, on activi-
7
ties carried out pursuant to exemptions granted— 
8
(1) to a State (including the District of Colum-
9
bia or any territory of the United States) or an 
10
opioid treatment program; 
11
(2) pursuant to section 8.11(h) of title 42, Code 
12
of Federal Regulations; and 
13
(3) during the period— 
14
(A) beginning on the declaration of the 
15
public health emergency for the COVID–19 
16
pandemic under section 319 of the Public 
17
Health Service Act (42 U.S.C. 274); and 
18
(B) ending on the earlier of— 
19
(i) the termination of such public 
20
health emergency, including extensions 
21
thereof pursuant to such section 319; and 
22
(ii) the end of calendar year 2022. 
23
(b) ISSUES TO BE STUDIED.—The study under sub-
24
section (a) shall, with respect to exemptions described in 
25
22:28 Jul 22, 2022
H6279
3 
HR 6279 IH1S 
such subsection, include consideration of each of the fol-
1
lowing: 
2
(1) The number of participating patients in 
3
each State. 
4
(2) The percentage of participating patients in 
5
each State relative to the total number of patients 
6
in the respective State receiving treatment through 
7
an opioid treatment program. 
8
(3) The number of participating patients in 
9
each State who cease treatment. 
10
(4) The number of participating patients in 
11
each State who overdose on an opioid and cease 
12
treatment. 
13
(5) The number of participating patients in 
14
each State who overdose on an opioid and continue 
15
treatment. 
16
(6) The number of participating opioid treat-
17
ment programs in each State. 
18
(7) The percentage of participating opioid treat-
19
ment programs in each State relative to the total 
20
number of opioid treatment programs in the respec-
21
tive State. 
22
(8) The demographic, socioeconomic, and geo-
23
graphic characteristics of the participating patients 
24
and opioid treatment programs. 
25
22:28 Jul 22, 2022
H6279
4 
HR 6279 IH1S 
(9) Any additional costs or savings from exemp-
1
tions in each State. 
2
(10) An analysis of differences in the use of ex-
3
emptions among States. 
4
(11) Rates of medication adherence and diver-
5
sion. 
6
(c) PRIVACY.—The section does not authorize the dis-
7
closure by the Department of Health and Human Services 
8
of individually identifiable information about patients. 
9
(d) FEEDBACK.—In conducting the study under sub-
10
section (a), the Assistant Secretary for Mental Health and 
11
Substance Use shall gather feedback from the States and 
12
opioid treatment programs on their experiences in imple-
13
menting exemptions described in subsection (a). 
14
(e) REPORT.—Not later than 180 days after the end 
15
of the period described in subsection (a)(3)(B), and sub-
16
ject to subsection (c), the Assistant Secretary for Mental 
17
Health and Substance Use shall publish a report on the 
18
results of the study under this section. 
19
SEC. 3. CHANGES TO FEDERAL OPIOID TREATMENT STAND-
20
ARDS. 
21
(a) MOBILE MEDICATION UNITS.—Section 302(e) of 
22
the Controlled Substances Act (21 U.S.C. 822(e)) is 
23
amended by adding at the end the following: 
24
22:28 Jul 22, 2022
H6279
5 
HR 6279 IH1S 
‘‘(3) Notwithstanding paragraph (1), a registrant 
1
that is dispensing pursuant to section 303(g) narcotic 
2
drugs to individuals for maintenance treatment or detoxi-
3
fication treatment shall not be required to have a separate 
4
registration to incorporate one or more mobile medication 
5
units into the registrant’s practice to dispense such nar-
6
cotics at locations other than the registrant’s principal 
7
place of business or professional practice described in 
8
paragraph (1), so long as the registrant meets such stand-
9
ards for operation of a mobile medication unit as the At-
10
torney General may establish.’’. 
11
(b) CLARIFICATION
IN
CONSIDERATION
OF
PA-
12
TIENTS’ RESPONSIBILITY IN HANDLING OPIOID DRUGS 
13
FOR UNSUPERVISED USE.—Not later than 90 days after 
14
the date of enactment of this Act, the Secretary of Health 
15
and Human Services shall promulgate a final regulation, 
16
or issue guidance, clarifying section 8.12(i)(2)(i) of title 
17
42, Code of Federal Regulations (and making such other 
18
changes as may be necessary) so that a medical director, 
19
in determining whether a patient is sufficiently responsible 
20
in handling opioid drugs for unsupervised use, as de-
21
scribed in such section 8.12(i)(2) of such title 42, shall 
22
not consider whether the patient has an absence of recent 
23
abuse of drugs (opioid or nonnarcotic), including alcohol, 
24
as the sole consideration in determining whether a patient 
25
22:28 Jul 22, 2022
H6279
6 
HR 6279 IH1S 
is sufficiently responsible in handling opioid drugs for un-
1
supervised use, as described in such section 8.12(i)(2). 
2
(c) PERIODS FOR TAKE-HOME SUPPLY REQUIRE-
3
MENTS.— 
4
(1) FIRST
REGULATION.—Not later than 90 
5
days after the date of enactment of this Act, the 
6
Secretary of Health and Human Services shall pro-
7
mulgate a final regulation amending paragraphs 
8
(i)(3)(i) through (i)(3)(vi) of section 8.12 of title 42, 
9
Code of Federal Regulations (and making such other 
10
changes as may be necessary) so that— 
11
(A) the references to 90 days in para-
12
graphs (i)(3)(i) through (i)(3)(iii) of such sec-
13
tion 8.12 are each reduced to not more than 45 
14
days; 
15
(B) the reference to the remaining months 
16
of the first year in paragraph (i)(3)(iv) of such 
17
section 8.12 is reduced to the remaining days of 
18
not more than the first six months of treat-
19
ment; 
20
(C) the reference to 1 year in paragraph 
21
(i)(3)(v) of such section 8.12 is reduced to not 
22
more than 6 months; and 
23
22:28 Jul 22, 2022
H6279
7 
HR 6279 IH1S 
(D) the reference to 2 years in paragraph 
1
(i)(3)(vi) of such section 8.12 is reduced to not 
2
more than 1 year. 
3
(2) STUDY.—Not later than 18 months after 
4
the date of enactment of this Act, the Assistant Sec-
5
retary for Mental Health and Substance Use shall— 
6
(A) complete a study, in consultation with 
7
patients and other stakeholders, on the impacts 
8
on patient rehabilitation of the changes made 
9
by the regulation under paragraph (1) to the 
10
periods specified in section 8.12(i)(3) of title 
11
42, Code of Federal Regulations; 
12
(B) submit a report to the Congress on the 
13
results of such study; and 
14
(C) include in such report recommenda-
15
tions for policy changes. 
16
(3) SECOND REGULATION.— 
17
(A) IN
GENERAL.—Not later than two 
18
years after the date of enactment of this Act, 
19
the Secretary of Health and Human Services 
20
shall promulgate a final regulation amending 
21
paragraphs (i)(3)(i) through (i)(3)(vi) of section 
22
8.12 of title 42, Code of Federal Regulations, 
23
as appropriate based on the findings of the 
24
study under paragraph (2). 
25
22:28 Jul 22, 2022
H6279
8 
HR 6279 IH1S 
(B) LIMITATION.—The regulation under 
1
subparagraph (A) shall not amend section 8.12 
2
of title 42, Code of Federal Regulations, so as 
3
to— 
4
(i) allow the dispensing of more than 
5
two consecutive doses of methadone for 
6
take-home use per week before the pa-
7
tient’s 30th day of treatment; or 
8
(ii) prohibit a patient determined to 
9
be responsible in handling opioids from 
10
being given a maximum of a one-month 
11
supply of methadone for take-home use 
12
after two years of continuous treatment. 
13
SEC. 4. EXPANSION OF TAKE-HOME PRESCRIBING OF 
14
METHADONE THROUGH PHARMACIES. 
15
(a) 
REGISTRATION; 
OTHER
CARE
BY
TELE-
16
HEALTH.—Section 303(g) of the Controlled Substances 
17
Act (21 U.S.C. 823(g)) is amended— 
18
(1) in paragraph (1), by striking ‘‘in paragraph 
19
(2)’’ and inserting ‘‘in paragraphs (2) and (3)’’; and 
20
(2) by adding at the end the following: 
21
‘‘(3)(A) At the request of a State, the Attorney Gen-
22
eral, in consultation with the Secretary, may, pursuant to 
23
paragraph (1), register persons described in subparagraph 
24
22:28 Jul 22, 2022
H6279
9 
HR 6279 IH1S 
(B) to prescribe methadone to be dispensed through a 
1
pharmacy for individuals for unsupervised use. 
2
‘‘(B) Persons described in this subparagraph are per-
3
sons who— 
4
‘‘(i) are licensed, registered, or otherwise per-
5
mitted, by the United States or the jurisdiction in 
6
which they practice, to prescribe controlled sub-
7
stances in the course of professional practice; and 
8
‘‘(ii) are— 
9
‘‘(I) employees or contractors of an opioid 
10
treatment program; or 
11
‘‘(II) addiction medicine physicians or ad-
12
diction psychiatrists who hold a subspecialty 
13
board certification in addiction medicine from 
14
the American Board of Preventive Medicine, a 
15
board certification in addiction medicine from 
16
the American Board of Addiction Medicine, a 
17
subspecialty board certification in addiction 
18
psychiatry from the American Board of Psychi-
19
atry and Neurology, or a subspecialty board 
20
certification in addiction medicine from the 
21
American Osteopathic Association. 
22
‘‘(C) The prescribing of methadone pursuant to sub-
23
paragraph (A) shall be— 
24
‘‘(i) exclusively by electronic prescribing; 
25
22:28 Jul 22, 2022
H6279
10 
HR 6279 IH1S 
‘‘(ii) for a supply of not more than 1 month 
1
pursuant to each prescription; and 
2
‘‘(iii) subject to the restrictions listed in section 
3
8.12(i)(3) of title 42, Code of Federal Regulations, 
4
including any amendments or exemptions to such 
5
section pursuant to section 3(c) of the Opioid Treat-
6
ment Access Act of 2022, or successor regulations or 
7
guidance. 
8
‘‘(D) The dispensing of methadone to an individual 
9
pursuant to subparagraph (A) shall be in addition to the 
10
other care which the individual continues to have access 
11
to through an opioid treatment program. 
12
‘‘(E) Persons registered in a State pursuant to sub-
13
paragraph (A) shall— 
14
‘‘(i) ensure and document, with respect to each 
15
patient treated pursuant to subparagraph (A), in-
16
formed consent to treatment; and 
17
‘‘(ii) include in such informed consent, specific 
18
informed consent regarding differences in confiden-
19
tiality 
protections 
applicable 
when 
dispensing 
20
through an opioid treatment program versus dis-
21
pensing through a pharmacy pursuant to subpara-
22
graph (A). 
23
‘‘(F) At the request of a State, the Attorney General, 
24
in consultation with the Secretary, shall— 
25
22:28 Jul 22, 2022
H6279
11 
HR 6279 IH1S 
‘‘(i) cease registering persons in the State pur-
1
suant to subparagraph (A); and 
2
‘‘(ii) withdraw any such registration in effect 
3
for a person in the State. 
4
‘‘(G) Maintenance treatment or detoxification treat-
5
ment provided pursuant to subparagraph (A), as well as 
6
other care provided in conjunction with such treatment, 
7
such as counseling and other ancillary services, may be 
8
provided by means of telehealth as determined jointly by 
9
the State and the Secretary to be feasible and appro-
10
priate.’’. 
11
(b) ANNUAL REPORTING.—Not later than 6 months 
12
after the date of enactment of this Act, and annually 
13
thereafter, the Assistant Secretary for Mental Health and 
14
Substance Use and the Administrator of the Drug En-
15
forcement Agency, acting jointly, shall submit a report to 
16
the Congress including— 
17
(1) the number of persons registered pursuant 
18
to section 303(g)(3) of the Controlled Substances 
19
Act, as added by subsection (a); 
20
(2) the number of patients being prescribed 
21
methadone pursuant to such section 303(g)(3); and 
22
(3) a list of the States in which persons are 
23
registered pursuant to such section 303(g)(3). 
24
22:28 Jul 22, 2022
H6279
12 
HR 6279 IH1S 
SEC. 5. SENSE OF CONGRESS ON NEED TO REDUCE BAR-
1
RIERS TO PATIENT CARE THROUGH OPIOID 
2
TREATMENT PROGRAMS. 
3
It is the sense of the Congress that— 
4
(1) patients receiving services through opioid 
5
treatment programs face barriers to their care; and 
6
(2) each State should align its regulation of 
7
opioid treatment programs in a manner that is con-
8
sistent with the intent of this Act. 
9
Æ 
22:28 Jul 22, 2022
H6279
